US2019376033A1PendingUtilityA1
PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCs) FOR DIAGNOSTIC TESTING
Est. expiryMay 15, 2034(~7.8 yrs left)· nominal 20-yr term from priority
C12Q 1/6883C12Q 2565/501G01N 2800/385C12Q 2531/113G01N 33/6893C12Q 2600/158C12Q 2600/156G01N 33/80G01N 2800/387C12Q 1/6806C12N 5/0641G01N 33/6878C07K 16/2896G01N 33/56966G01N 33/54326G01N 33/582C07K 16/2881
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The disclosure relates to methods of preparation of fetal nucleated red blood cells (NRBCs) from biological samples for diagnostic testing.
Claims
exact text as granted — not AI-modified1 . A method of enriching for fetal nucleated red blood cells (fNRBCs) from a biological sample, comprising:
(a) subjecting the biological sample to density separation to obtain a fNRBC-containing cell fraction; (b) subjecting the fNRBC-containing cell fraction obtained in step (a) to magnetic activated cell sorting (MACS) using at least one fNRBC positive selection reagent to obtain a MACS-sorted cell population; (c) fluorescently labeling cells in the MACS-sorted cell population obtained in step (b) with at least one fNRBC positive selection reagent to obtain a fluorescently labeled cell population; and (d) sorting the fluorescently labeled cell population obtained in step (c) by flow cytometry to select for fNRBCs, thereby obtaining a population of cells enriched for fNRBCs.
2 - 3 . (canceled)
4 . The method of claim 1 , wherein at least one fNRBC positive selection reagent of step (b) comprises monoclonal antibody 4B9, an anti-CD235a antibody, or a nuclear stain.
5 - 9 . (canceled)
10 . The method of claim 1 , which does not comprise a negative selection step.
11 . The method of claim 1 , wherein the fNRBC-containing cell fraction obtained in step (a) is subject to negative selection prior to step (b).
12 . The method of claim 1 , wherein the MACS-sorted cell population obtained in step (b) is subject to negative selection prior to step (c).
13 . The method of claim 11 , wherein the negative selection is negative immunoselection.
14 . (canceled)
15 . A method of enriching for fNRBCs from a biological sample, comprising:
(a) subjecting the biological sample to density separation to obtain a fNRBC-containing cell fraction; (b) subjecting the fNRBC-containing cell fraction obtained in step (a) to MACS using at least two fNRBC positive selection reagents to obtain a MACS-sorted cell population; (c) performing micromanipulation on the MACS-sorted cell population obtained in step (b) to isolate individual fNRBCs or groups of fNRBCs.
16 . The method of claim 15 , wherein at least one fNRBC positive selection reagent of step (b) comprises monoclonal antibody 4B9 or an anti-CD235a antibody.
17 . (canceled)
18 . The method of claim 15 , which does not comprise a negative selection step.
19 . The method of claim 15 , wherein the fNRBC-containing cell fraction obtained in step (a) is subject to negative selection prior to step (b).
20 . The method of claim 15 , wherein the MACS-sorted cell population obtained in step (b) is subject to negative selection prior to step (c).
21 . The method of claim 19 , wherein the negative selection is negative immunoselection.
22 . (canceled)
23 . The method of claim 1 , wherein the biological sample is maternal blood.
24 - 25 . (canceled)
26 . The method of claim 1 , which further comprises validating the identity of at least one fNRBC as a fetal cell.
27 . A cell population enriched in fNRBCs obtained or obtainable by the method of claim 1 .
28 . A FACS-sorted cell population containing (a) at least 2, at least 5 or at least 10 and/or (b) up to 15, up to 25, or up to 35 fNRBCs enriched from maternal blood.
29 - 30 . (canceled)
31 . A method of detecting a fetal abnormality, comprising analyzing at least one fNRBC from the cell population of claim 27 for a fetal abnormality.
32 . (canceled)
33 . The method of claim 31 , which comprises analyzing a single fNRBC for the fetal abnormality.
34 . The method of claim 31 , which comprises analyzing a group of fNRBCs for the fetal abnormality.
35 - 38 . (canceled)
39 . The method of claim 31 , which further comprises validating the fNRBC or fNRBCs as fetal cells.
40 - 42 . (canceled)Join the waitlist — get patent alerts
Track US2019376033A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.